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Abstract
Background: MicroRNAs (miRNAs) are short, noncoding RNAs that regulate the expression of multiple target genes.
Deregulation of miRNAs is common in human tumorigenesis. The miRNAs, MIR-15a/16-1, at chromosome band 13q14 are
down-regulated in the majority of patients with chronic lymphocytic leukaemia (CLL).
Methodology/Principal Findings: We have measured the expression of MIR-15a/16-1, and 92 computationally-predicted
MIR-15a/16-1 target genes in CLL patients and in normal controls. We identified 35 genes that are deregulated in CLL
patients, 5 of which appear to be specific targets of the MIR-15a/16-1 cluster. These targets included 2 genes (BAZ2A and
RNF41) that were significantly up-regulated (p,0.05) and 3 genes (RASSF5, MKK3 and LRIG1) that were significantly down-
regulated (p,0.05) in CLL patients with down-regulated MIR-15a/16-1 expression.
Significance: The genes identified here as being subject to MIR-15a/16-1 regulation could represent direct or indirect
targets of these miRNAs. Many of these are good biological candidates for involvement in tumorigenesis and as such, may
be important in the aetiology of CLL.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia in the Western world. It is a heterogeneous disease
associated with a highly variable clinical course [1]. A key feature of
CLL is cytogenetic instability, with chromosomal abnormalities
occurring in around 80% of cases [2]. While the molecular aetiology
of CLL remains largely undetermined, specific recurrent chromo-
somal aberrations have been well described and serve as independent
prognostic indicators for disease progression and survival [2].
Deletion of chromosome 13q is the most frequent chromosomal
aberration in CLL, occurring in approximately 50% of patients
[2]. The deletion of chromosome band 13q14 has also been
reported in a variety of other malignancies [3–5], demonstrating
the importance of this region in tumorigenesis. There has been
wide speculation that the 13q14 region harbours tumour
suppressor gene(s) involved in the aetiology of these diseases
[6,7]. Various candidate tumour suppressor genes within the
minimal deleted region (MDR) at 13q14 have been investigated,
yet studies have consistently failed to detect any pathogenic
mutations [8–10]. There remains, therefore, a need to identify
alternative mechanisms that may influence the development of
CLL.
There is increasing evidence for the involvement of microRNAs
(miRNAs) in tumorigenesis [11–15]. MicroRNAs are small, non-
coding RNAs that mediate the expression of target genes through
sequence-specific base pairing with target messenger RNA
(mRNA) [16]. Target gene expression is regulated by the
degradation of the mRNA or more commonly, through blocking
translation [17–19]. Deregulation of miRNAs has been implicated
in human tumorigenesis and many miRNAs are located in
genomic regions involved in cancer [20].
Two miRNAs, MIR-15a and MIR-16-1, are located at
chromosome band 13q14 and are down-regulated in the majority
of patients with CLL [21]. These genes induce apoptosis through
the negative regulation of the anti-apoptotic gene BCL2 [22]. As
such, down-regulation of MIR-15a/16-1 has been associated with
the pathogenesis of CLL, although this remains controversial [23].
Each miRNA has the potential to mediate the expression of
many target genes [19]. It is therefore possible that MIR-15a/16-1
may regulate the expression of genes, other than BCL2, which may
be important in the development of CLL. Indeed, a recent study
combining experimental and bioinformatic data identified a MIR-
15a/16-1 gene signature in leukaemic cells [24]. The aim of this
study was to examine the expression patterns of computationally-
predicted targets of MIR-15a/16-1 to identify further novel
candidate genes involved in the aetiology of CLL.
Materials and Methods
Ethics Statement
Ethical approval was granted by the North and East Devon
Local Research Ethics Committee and all patients provided
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written informed consent in accordance with the Declaration of
Helsinki.
Patients
Thirteen patients with CLL under the care of the Haematology
Unit at the Royal Devon and Exeter Hospital were enrolled in this
study. Each patient had an established diagnosis of CLL based on
current World Health Organization (WHO) classification guide-
lines [25]. Patients had a history of persistent lymphocytosis
.56109/l and an immunophenotypic profile typical of CLL [26].
The majority of patients (12/13) had received treatment for their
disease prior to involvement in this study. Of the 13 CLL patients
included in this study, 7 (54%) had a deletion at 13q14 confirmed
by fluorescence in situ hybridisation (FISH) and multiplex ligation-
dependent probe amplification (MLPA) (data not shown). Five
normal control samples from healthy volunteers were also
obtained for this study.
RNA Extraction
Total RNA was extracted from whole blood using the MirVana
miRNA Isolation kit (Ambion/Applied Biosystems, Foster City,
USA), according to the manufacturer’s instructions. RNA
concentrations were measured using a ND-1000 spectrophotom-
eter (NanoDrop Technologies, Wilmington, USA).
MicroRNA-15a/16-1Expression
MicroRNA-15a/16-1 expression was determined for each sample
using the TaqMan MicroRNA assays kit (Applied Biosystems,
Foster City, USA), according to the manufacturer’s instructions.
The protocol involves real-time quantification of microRNAs by
stem-loop RT-PCR, as previously described [27]. All PCR
reactions were performed in triplicate. Crossing points (Ct) were
determined for each miRNA and an endogenous control gene (beta
glucorinidase (GUSB). The relative abundance of each miRNA
transcript was then determined using the comparative Ct method
[28]. Down-regulated miR-15a/16-1 expression in CLL patients
was defined as a $50% reduction in the expression levels of either
MIR-15a or MIR-16-1 when compared with the average MIR-15a
and MIR-16-1 expression levels in the normal control subjects.
Tiled Low Density Array (TLDA) Analysis
Reverse Transcription. Total RNA (1 mg) was reversed
transcribed in 50 ml reactions using the TaqMan Reverse
Transcription kit (Applied Biosystems, Foster City, USA),
according to the manufacturer’s instructions. PCR amplification
of the endogenous GUSB gene was performed to ensure that the
resulting cDNA samples were of adequate quality. PCR reactions
were performed in triplicate on the ABI 7900HT Prism (Applied
Biosystems, Foster City, USA). Probe and primer sequences are
available on request. Each 25 ml reaction included 5 ml universal
master mix, (no AMPerase) (Applied Biosystems, Foster City
USA), 5.0 mM probe, 20 mM each primer and 2 ml of cDNA. PCR
cycles were 50uC for 2 minutes, 95uC for 10 minutes followed by
60 cycles of 95uC for 15 seconds and 60uC for 1 minute. The
cDNA was considered adequate quality when GUSB amplification
was observed in all three reactions with minimal difference
between crossing points.
TLDA. TLDA allows for the simultaneous detection of the
expression of 384 genes per card. In the present study, TLDA
cards were configured into four identical 96-gene sets, allowing
two samples to be run in duplicate per card.
The web-based programmesTargetScanS (http://www.targetscan.
org/) and PicTar (http://pictar.mdc-berlin.de/) were used to predict
potential targets ofMIR-15a/16-1 for inclusion on the TLDA cards.
TargetScanS predicts biological targets of miRNAs by searching for
the presence of conserved 8mer and 7mer sites that match the seed
region (nucleotides 2–7 at the 59 end segment of the MIRNA) of
each miRNA [29], while PicTar is a sophisticated algorithm that
predicts miRNA targets by searching for pair-wise alignments that
are conserved across species [30]. Genes were selected for inclusion
on the TLDA cards if the following criteria were satisfied: (1) the
genes were predicted as targets of MIR-15a/16-1 by both
computational programmes (TargetScanS and Pictar), and (2)
Searches with Pubmed showed good biological evidence for
potential involvement in tumorigenesis (Eg. proto-oncogenes,
tumour-suppressor genes, transcription factors or genes involved
in cell cycle regulation). Each 96-gene set included 92 predicted
targets of MIR-15a/16-1 as well as four endogenous control genes;
18S, ACTB, GUSB and B2M.
For each patient sample, a reaction mix of 400 ml was prepared,
including 200 ml 2x TaqMan universal master mix (no AMPerase)
(Applied Biosystems, Foster City, USA), 160 ml dH2O and 40 ml
cDNA template. Aliquots (100 ml) of the reaction mix were added
to the appropriate sample loading ports on the TLDA card. The
cards were centrifuged twice for 1 minute at 12,000 rpm to allow
distribution of the reaction mix to each of the reaction wells. PCR
amplifications were performed on the ABI 7900HT platform
(Applied Biosystems, Foster City, USA). Cycling conditions were
50uC for 2 minutes, 94.5uC for 10 minutes followed by 40 cycles of
97uC for 30 seconds and 57.9uC for 1 minute. The expression of
each gene was measured in duplicate for each patient.
Analysis of gene expression
The abundance of each transcript in the TLDA analysis is
directly proportional to the point in the reaction where the signal
appears above the background fluorescence levels. This is termed
the crossing point (Ct). Differences in the abundance of two targets
are therefore directly proportional to the differences in their
crossing points (DCt). We calculated the difference between the
crossing point (DCt) for each test target (Cttest) compared with the
average crossing point of four endogenous control genes (18S,
ACTB, GUSB and B2M) (CtAveEC) in each sample. The level of
each transcript relative to that of the endogenous control levels for
any given sample could then be calculated from the equation
22DDCt [28] where DDCt is the DCt value of the test transcript in
that sample (DCttest) normalised to a reference transcript which
was taken to be the average levels of BCL2 in normal controls
(DCtref).
Gene Ontology Analysis
The Gene Ontology (GO) categories of genes that were
differentially expressed in CLL patients and normal controls were
analysed with the ‘PANTHER Classification System’ GO browser
tool. (http://www.pantherdb.org/).
Analysis of Adenylate Uridylate-Rich Elements (ARE)
Deregulated targets of the MIR-15a/16-1 cluster were analysed
for the presence of AU-rich elements which have been reported to
mediate mRNA stability (ref). Analysis was performed using the
ARE-mRNA database version 3.0 (ARED; http://rc.kfshrc.edu.
sa/ared/).
Protein Expression Analysis
Where possible, protein expression analysis of the putativeMIR-
15a/16-1 target genes in CLL was investigated using the ‘The
MIR-15a/16-1 Targets in CLL
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Human Protein Atlas’ bioinformatics tool (http://www.proteinatlas.
org/).
Statistical Analysis
Statistical analysis was performed using SPSS 11.0 (SPSS, Inc.,
Chicago, IL, USA). The comparison of target gene expression
between different patient groups was performed using the Mann-
Whitney U test. A P value of ,0.05 was considered statistically
significant.
Results
MicroRNA-15a/16-1Expression
MicroRNA-15a/16-1 expression was down-regulated in the
majority of CLL patients (10/13, 77%), including each patient
with an identified deletion at 13q14. In the majority of cases,
down-regulation of MIR-15a/16-1 correlated with chromosome
13q14 deletion status (Table 1), but in three cases (CLL 03, CLL
11 and CLL 13) the MIR-15a/16-1 cluster was down-regulated in
the absence of an identifiable 13q14 deletion.
Assessment of Sample Quality for TLDA Analysis
RNA was extracted and reverse transcribed for all subjects as
described above. GUSB was successfully amplified in triplicate in
all 18 cases (data not shown), indicating that the cDNA was of
adequate quality to perform TLDA analysis.
Micro RNA Target Prediction
A total of 99 and 145 potential gene targets were predicted by
the web-based programmes (TargetScanS and PicTar) for MIR-15a
and MIR-16-1 respectively. Of these putative targets, 92 genes
with a high likelihood for involvement in tumorigenesis were
selected for inclusion on the TLDA cards.
Differentially expressed genes in patients with CLL and
Normal Controls
Real-time PCR amplification detected the expression of 80/92
(87%) target genes and all four endogenous control genes in both
the CLL and the normal control patient cohorts. TLDA analysis
identified 35 genes that were differentially expressed (p,0.05)
between the CLL and normal control patients (Figure 1). Of these
genes, 27 (77%) were up-regulated and 8 (23%) were down-
regulated in the patients with CLL compared with the normal
controls.
The GO of the differentially expressed genes in CLL patients
and normal controls was assessed with the ‘PANTHER Classifi-
cation System’ (http://www.pantherdb.org/). The most frequently
represented GO categories included: (1) transcription factor, (2)
cell cycle and (3) signal transduction. Other significant GO
categories represented included; apoptosis, inhibition of apoptosis,
nucleic acid metabolism, regulatory molecule and kinase.
Genes specifically deregulated by the down-regulation of
the MIR-15a/16-1 cluster
Of the 92 gene targets assessed, TLDA analysis identified 5 (5%)
that may be specifically deregulated by the down-regulation of the
MIR-15a/16-1 cluster. Of these 5 differentially expressed genes, 2
(BAZ2A and RNF41) were up-regulated (Figure 2) and 3 (RASSF5,
MKK3, and LRIG1) were down-regulated (Figure 3) in CLL
patients with low levels of MIR-15a/16-1 expression. The putative
MIR-15a/16-1 targets were investigated for the presence of AU-
rich elements, which have been implicated in regulation of mRNA
stability. Of the 5 identified targets, 3 (BAZ2A, RNF41 and LRIG1)
contained AREs in their 39 UTR.
Protein expression analysis of the putative MIR-15a/16-1
target genes
Protein expression data from ‘The Human Protein Atlas’
(http://www.proteinatlas.org/) bioinformatics tool was available
for RNF41 and MKK3. This data provided evidence for the up-
regulation of RNF41 in B-CLL, since immunohistochemistry
analysis demonstrated weak-moderated expression of RNF41 in B-
CLL samples, while peripheral blood mononuclear cells from
healthy blood donors showed negative-weak expression of the
protein. MKK3 protein expression data showed that malignant
lymphoma tissues typically exhibited weak cytoplasmic immuno-
reactivity or were negative. Protein expression analysis in CLL
subjects for the BAZ2A, RASSF5 and LRIG1 genes is currently
unavailable and represents an interesting area for future research.
Discussion
We have investigated the expression patterns of 92 computa-
tionally-predicted targets of MIR-15a/16-1 in 13 patients with
CLL and 5 normal controls using TLDA analysis. We identified
35 genes that are differentially regulated in patients with CLL
compared with normal controls and 5 genes which may be
specifically regulated by the MIR-15a/16-1 cluster at chromosome
band 13q14. These genes may be important in the aetiology of
CLL and as such, provide interesting targets for future studies.
A comparison of the expression profiles of CLL patients and
normal controls identified 35 differentially regulated genes
(Figure 1), the majority of which (77%) were up-regulated in the
CLL patient group. Gene ontology analysis demonstrated that
many of the differentially regulated genes were transcription
factors, cell cycle-related genes or genes involved in signal
transduction. Although not specifically regulated by the MIR-
15a/16-1 cluster, these deregulated genes may represent impor-
tant contributors to the process of leukaemogenesis.
The 5 genes specifically regulated by MIR-15a/16-1 expression
included 2 genes (BAZ2A and RNF41) that were significantly up-
regulated in CLL patients with low MIR-15a/16-1 expression
(Figure 2). These genes may represent direct biological targets of
Table 1. Summary of MicroRNA-15a/16-1 expression levels
and chromosome band 13q14 deletion status.
Identifier MicroRNA-15/16-1 Expression 13q14 Deletion Status
CLL 01 Down-regulated Deleted
CLL 02 Down-regulated Deleted
CLL 03 Down-regulated Not Deleted
CLL 04 Normal Not Deleted
CLL 05 Normal Not Deleted
CLL 06 Down-regulated Deleted
CLL 07 Normal Not Deleted
CLL 08 Down-regulated Deleted
CLL 09 Down-regulated Deleted
CLL 10 Down-regulated Deleted
CLL 11 Down-regulated Not Deleted
CLL 12 Down-regulated Deleted
CLL 13 Down-regulated Not Deleted
Discrepancies are highlighted in bold.
doi:10.1371/journal.pone.0007169.t001
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the MIR-15a/16-1 cluster. Further experimental work including
luciferase reporter gene assays or mutagenesis of predicted miRNA
binding sites may be useful to examine these possibilities further. A
further 3 genes (RASSF5, MKK3 and LRIG1) were expressed at
significantly lower levels in CLL patients with down-regulated
MIR-15a/16-1 expression (Figure 3). These genes may be indirect
targets of MIR-15a/16-1, their expression perhaps being repressed
by another, as yet unidentified, direct target of the MIR-15a/16-1
cluster.
Further evidence for the deregulation of the target genes we
identified in CLL was obtained from protein expression data
(http://www.oriteubatkas,irg/). This analysis confirmed the up-
regulation of RNF41 in B-CLL subjects. It also demonstrated weak
or negative MKK3 protein expression in malignant lymphoma
tissues, consistent with our data. The functions of the identified
MIR-15a/16-1 target genes are discussed further below. Protein
data were not available for the remaining three targets we
identified. This represents an interesting area for future work.
BAZ2A is a member of the bromodomain family of genes which
function as integral components of chromatin re-modelling
complexes [31]. They are believed to play a role in the
chromatin-dependent regulation of transcription. Interestingly,
putative BAZ2A deregulation has been implicated in a paediatric
case of pre-B acute lymphoblastic leukemia (ALL) in which a
cryptic rearrangement between 12p13 and 12q13 generated a
fusion of ETV with an intronic sequence of BAZ2A [32]. The
authors do acknowledge, however, that the leukaemogenic impact
of putative BAZ2A deregulation remains undetermined at present
[32].
RNF41 is an evolutionarily conserved RING finger-containing
ubiquitin ligase It has been speculated that RNF41 is involved in
the aetiology of haematological malignancies [33]. The gene
resides at chromosome band 12q13, a locus that frequently
demonstrates aberrations associated with acute myeloid leukemia
(AML) or non-Hodgkin’s lymphoma (NHL) [33]. Additionally, the
gene is differentially expressed in foetal and adult haematopoietic
stem cells and progenitors [33], suggesting that it may be involved
in cell lineage commitment and differentiation [33]. A recent study
demonstrated that over-expression of RNF41 in a murine
multipotent haematopoietic progenitor cell line (EML) attenuated
erythroid and myeloid differentiation in response to the cytokines
erythropoietin (EPO), interleukin-3 (IL-3) and retinoic acid [34].
This response resulted from RNF41-specific regulation of cytokine
receptor levels [34]. Further studies are required to determine
whether other haematopoietic cytokine receptors are regulated by
RNF41 and whether the gene additionally influences haematopoi-
etic progenitor cell differentiation into lymphoid lineages.
RASSF5 is a member of the RAS association domain family. It
can act as a tumour suppressor by inducing apoptosis and delaying
cell cycle progression in different cancer cell lines [35]. The gene is
epigenetically silenced in a variety of human cancers by CpG
island promoter hypermethylation [36,37]. Interestingly, miRNAs
can themselves act as epigenetic modifiers by the post-transcrip-
tional regulation of chromatin modifying enzymes [38].
The mitogen-activated protein (MAP) kinase pathways mediate
the transduction of extracellular signals via protein phosporylation
cascades. Three distinct MAP kinase pathways have been defined;
(1) extracellular-signal-related kinases (ERKs), (2) the c-Jun N-
terminal kinases (JNKs) and (3) p38 stress-activated protein kinases
(p38 MAPKs) [39]. MKK3 is one of the upstream activator kinases
for the p38 MAPK pathway. A recent study demonstrated that the
p38 MAPK pathway, including MKK3, is constitutively activated
in B-CLL cells but not their normal peripheral B-cell counterpart
[40]. The constitutive p38 MAPK pathway activation results in
Figure 1. Differentially expressed genes in patients with CLL and normal controls. Bar graph representing the difference in relative gene
expression in CLL patients compared with normal control patients. The dark grey bars above the x-axis represent genes that are significantly up-
regulated in CLL patients compared with normal controls. Light grey bars below the x-axis represent genes that are significantly down-regulated in
CLL patients when compared to normal controls. P-values; * represents ,0.05, and ** represents ,0.01
doi:10.1371/journal.pone.0007169.g001
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up-regulation of matrix metalloproteinase-9 (MMP-9) [40], a
critical factor in tumour angiogenesis and tumour homing.
Elevated serum levels of MMP-9 are associated with an
unfavourable prognosis for patients with CLL [41]. Our study
identified significantly lower levels of MKK3 expression in CLL
patients with down-regulated MIR-15a/16-1. This is consistent
with CLL patients harbouring chromosome 13q14 deletions, and
hence MIR-15a/16-1 down-regulation, displaying a more favour-
able prognosis [2].
LRIG1 is a member of a family of LRIG genes that encode
integral membrane proteins with extracellular/lumenal extensions
consisting of leucine-rich and immuloglobulin-like domains [42].
LRIG1 interacts with the ErbB receptor tyrosine kinase to
negatively regulate EGFR signalling [43]. This regulation is
mediated through the recruitment of E3 ubiquitin ligases, resulting
in ubiquitinylation, internalisation and lysosomal degradation of
the ErbB receptors. LRIG1 is a proposed tumour suppressor gene.
It localizes at chromosome band 3p14.3, a chromosomal region
that is commonly deleted in human cancers. Additionally, LRIG1
is down-regulated in a variety of different tumour cell lines [44]
consistent with it being a tumour suppressor gene. It has been
hypothesised that the down-regulation of LRIG1 could unleash
EGFR signalling which may contribute to the development of
various malignancies [45]. Of note, however, LRIG1 expression is
up-regulated in some tumours, suggesting that the gene functions
as a tumour promoter under certain circumstances [45]. Further
studies are required to unravel the functions of the LRIG proteins
and to further understand the contribution of LRIG1 dysregulation
to human tumorigenesis.
The majority (87/92, 95%) of the computationally-predicted
targets investigated in this study were not differentially regulated in
Figure 2. Significantly up-regulated genes in CLL patients with
down-regulated miR-15a/16-1 expression. Boxplot graphs repre-
senting the relative up-regulation of genes BAZ2A and RNF41 in CLL
patients with down-regulated miR-15a/16-1 expression compared with
CLL patients with normal miR-15a/16-1 expression.
doi:10.1371/journal.pone.0007169.g002 Figure 3. Significantly down-regulated genes in CLL patients
with down-regulated miR-15a/16-1 expression. Boxplot graphs
representing the relative down-regulation of genes RASSF5, MKK3 and
LRIG1 in CLL patients with down-regulated miR-15a/16-1 expression
compared with CLL patients with normal miR-15a/16-1 expression.
doi:10.1371/journal.pone.0007169.g003
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CLL patients with varying levels of MIR-15a/16-1 expression. A
possible explanation for this may be that the analysis was performed
on mRNA rather than on proteins. Through imperfect pairing with
their target mRNAs, some miRNAs can reduce the protein levels of a
target gene with minimal variation of the mRNA levels. Alternatively,
the low predictive power of the bioinformatics tools used for miRNA
gene target prediction may also have contributed to this finding.
Computational algorithms for the prediction of miRNA targets are
acknowledged to yield a large number of false-positive hits.
TargetScanS and PicTar are estimated to have a 22–31% and ,30%
false-positive rate respectively [46]. Our data suggests that these
figures may under-estimate the false-positive rates associated with
these programmes. Use of additional bioinformatics programmes,
such as miRanda (http://cbio.mskcc.org/cgi-bin/mirnaviewer/
mirnaviewer.pl), in combination may enhance the positive
predictive power of these commonly used tools.
The regulation of gene expression is often complex and
multifactoral. The removal of one regulatory element, such as
MIR-15a/16-1, may be compensated for by the altered expression
of other regulatory elements, thus maintaining the normal
expression of the target gene. This may also explain why our
study identified so few differentially regulated MIR-15a/16-1
targets. Interestingly, the expression patterns of the anti-apoptotic
gene BCL2 may support this hypothesis. Cimmino et al (2005)
demonstrated that MIR-15a/16-1 negatively regulate BCL2 [22],
although this relationship remains controversial [23]. In the
current study, BCL2 was significantly over-expressed in CLL
patients compared with normal controls (p = 0.001). The anti-
apoptotic gene was also up-regulated in CLL patients with low
MIR-15a/16-1 expression compared to those with normal
expression levels of the miRNAs, however, this did not reach the
level of significance (p = 0.161) probably due to the small sample
size in this study. Our data indicates that the regulation of BCL2
may be influenced by MIR-15a/16-1 as well as other regulatory
elements, exerting a combinatorial effect.
In conclusion, our work has investigated the expression patterns
of computationally-predicted targets of MIR-15a/16-1 in patients
with CLL using TLDA analysis. We have identified 35 genes that
are deregulated in patients with CLL and 5 genes that are
specifically deregulated by low levels of MIR-15a/16-1 expression.
The identified genes are all good biological candidates for
involvement in tumorigenesis and as such, may be important in
the aetiology of CLL. They provide interesting candidate genes for
future studies and may represent possible targets for therapeutic
intervention.
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